Table 2.
Association between different anion gap levels and outcomes among stroke patients.
| Cohort—Univariate | Model 1—Multivariate | Model 2—Multivariate | ||||
|---|---|---|---|---|---|---|
| Outcomes | Crude HR (95% CI) |
p Value | Adjusted HR (95% CI) |
p Value | Adjusted HR (95% CI) |
p Value |
| ICU Mortality | n = 1236 | 0.008 | n = 1229 | <0.001 | n = 11,217 | <0.001 |
| Category 1 | Reference | Reference | Reference | |||
| Category 2 | 1.58 (0.76–3.26) | 0.220 | 2.20 (1.01–4.79) | 0.048 | 2.36 (1.06–5.23) | 0.035 |
| Category 3 | 2.40 (1.21–4.76) | 0.012 | 3.47 (1.67–7.18) | 0.001 | 3.72 (1.76–7.88) | 0.001 |
| Category 4 | 2.91 (1.47–5.77) | 0.002 | 4.52 (2.16–9.48) | <0.001 | 5.51 (2.47–12.30) | <0.001 |
| In-hospital Mortality | n = 1236 | 0.001 | n = 1229 | <0.001 | n = 1217 | <0.001 |
| Category 1 | Reference | Reference | Reference | |||
| Category 2 | 1.80 (1.02–3.18) | 0.042 | 2.26 (1.25–4.07) | 0.007 | 2.41 (1.31–4.43) | 0.005 |
| Category 3 | 2.75 (1.59–4.73) | <0.001 | 3.21 (1.81–5.72) | <0.001 | 3.19 (1.77–5.76) | <0.001 |
| Category 4 | 2.77 (1.60–4.79) | <0.001 | 3.37 (1.86–6.09) | <0.001 | 3.57 (1.91–6.69) | <0.001 |
| Intracerebral Hemorrhage | n = 1236 | 0.071 | n = 1229 | 0.290 | n = 1217 | 0.630 |
| Category 1 | Reference | Reference | Reference | |||
| Category 2 | 0.92 (0.51–1.66) | 0.787 | 1.08 (0.55–2.12) | 0.828 | 1.03 (0.52–2.06) | 0.922 |
| Category 3 | 1.68 (0.97–2.91) | 0.062 | 1.70 (0.89–3.24) | 0.107 | 1.45 (0.75–2.82) | 0.272 |
| Category 4 | 1.46 (0.83–2.57) | 0.191 | 1.46 (0.74–2.88) | 0.269 | 1.19 (0.58–2.42) | 0.634 |
HR: hazard ratio; OR: odds ratio. Model 1: All results of Adj-HR were adjusted by age, gender, race, heart rate, mean blood pressure, respiratory rate, temperature, Charlson comorbidity Index, hyperlipidemia, congestive heart failure, diabetes mellitus, chronic kidney disease, atrial fibrillation, HAS-BLED score, acute physiology score III, systemic inflammatory response syndrome, sequential organ failure assessment score, antiplatelet agents, anticoagulation agents (novel oral anticoagulant). Model 2: All result of Adj-HR were adjusted by age, gender, race, heart rate, mean blood pressure, respiratory rate, temperature, Charlson comorbidity Index, hyperlipidemia, congestive heart failure, diabetes mellitus, chronic kidney disease, atrial fibrillation, HAS-BLED score, acute physiology score III, systemic inflammatory response syndrome, quick sequential organ failure assessment score, antiplatelet agents, anticoagulation agents (novel oral anticoagulant), white blood cell, hemoglobin, platelet, potassium, blood urea nitrogen, creatinine.